NSE - Free Realtime Quote INR

Aurobindo Pharma Limited (AUROPHARMA.NS)

1,138.50
-16.70
(-1.44%)
As of 9:15:33 AM GMT+5:30. Market Open.
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Total Revenue
313,781,300
313,781,300
287,045,000
246,171,300
233,665,500
Cost of Revenue
130,262,400
130,262,400
126,029,000
118,997,000
108,151,800
Gross Profit
183,518,900
183,518,900
161,016,000
127,174,300
125,513,700
Operating Expense
133,958,700
133,958,700
117,802,600
101,798,300
92,511,000
Operating Income
49,560,200
49,560,200
43,213,400
25,376,000
33,002,700
Net Non Operating Interest Income Expense
-4,572,400
-4,572,400
-2,897,100
54,100
-170,400
Pretax Income
48,744,300
48,744,300
45,718,500
26,125,000
33,727,400
Tax Provision
15,827,200
15,827,200
12,110,200
6,848,500
7,256,300
Net Income Common Stockholders
37,895,100
37,895,100
31,729,700
19,275,000
26,481,500
Diluted NI Available to Com Stockholders
37,895,100
37,895,100
31,729,700
19,275,000
26,481,500
Basic EPS
59.81
--
54.16
32.90
45.19
Diluted EPS
59.81
--
54.16
32.90
45.19
Basic Average Shares
633,591.37
--
585,851.18
585,938.61
585,938.61
Diluted Average Shares
633,591.37
--
585,851.18
585,938.61
585,938.61
Rent Expense Supplemental
--
--
1,204,200
1,337,600
1,241,900
Total Expenses
264,221,100
264,221,100
243,831,600
220,795,300
200,662,800
Net Income from Continuing & Discontinued Operation
37,895,100
37,895,100
31,729,700
19,275,000
26,481,500
Normalized Income
39,190,733.50
39,190,733.50
31,729,700
19,354,176.67
27,513,909.64
Interest Income
--
--
2,857,600
1,458,900
316,000
Interest Expense
4,572,400
4,572,400
2,897,100
1,289,500
368,400
Net Interest Income
-4,572,400
-4,572,400
-2,897,100
54,100
-170,400
EBIT
53,316,700
53,316,700
48,615,600
27,414,500
34,095,800
EBITDA
69,810,900
69,810,900
63,832,200
39,860,300
45,361,000
Reconciled Cost of Revenue
130,262,400
130,262,400
126,029,000
118,997,000
108,151,800
Reconciled Depreciation
16,494,200
16,494,200
15,216,600
12,445,800
11,265,200
Net Income from Continuing Operation Net Minority Interest
37,895,100
37,895,100
31,729,700
19,275,000
26,481,500
Total Unusual Items Excluding Goodwill
-1,918,600
-1,918,600
0
-107,300
-1,162,100
Total Unusual Items
-1,918,600
-1,918,600
0
-107,300
-1,162,100
Normalized EBITDA
71,729,500
71,729,500
63,832,200
39,967,600
46,523,100
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-622,966.50
-622,966.50
0
-28,123.33
-129,690.36
3/31/2022 - 1/15/1996

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

LUPIN.NS Lupin Limited
1,991.80
-1.55%
 
GRANULES.NS Granules India Limited
515.90
-1.53%
 
IPCALAB.NS Ipca Laboratories Limited
1,362.00
-1.52%
 
AJANTPHARM.NS Ajanta Pharma Limited
2,694.40
-1.31%
 
DIVISLAB.NS Divi's Laboratories Limited
6,648.00
-1.14%
 
ZYDUSLIFE.NS Zydus Lifesciences Limited
964.20
-1.49%
 
CIPLA.NS Cipla Limited
1,482.70
-1.33%
 
APLLTD.NS Alembic Pharmaceuticals Limited
991.20
-0.14%
 
AKUMS.NS AKUMS DRUGS AND PHARMA L
561.05
-1.46%
 
TORNTPHARM.NS Torrent Pharmaceuticals Limited
3,206.70
-1.60%